CRISPR Therapeutics and Sirius Therapeutics Announce First Patient Dosed in Phase 2 Trial of SRSD107 for Thromboembolic Disorders in Europe

ZUG, Switzerland and BOSTON and SAN DIEGO and SHANGHAI, Sept (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP), a ...
The Victoria Advocate

GenEditBio Announces First Patient Dosed in Investigator-Initiated Trial of GEB‑101, World's First In Vivo CRISPR-Cas Ribonucleoprotein-Based Genome Editing Investigational ...

HONG KONG, BEIJING and BOSTON, June 6, 2025 /PRNewswire/ -- GenEditBio Limited ("GenEditBio"), a clinical-stage biotechnology start-up company focusing on genome editing therapeutic solutions through ...

AI-powered CRISPR could lead to faster gene therapies

Stanford Medicine researchers have developed an artificial intelligence tool to help scientists better plan gene-editing experiments. The technology, CRISPR-GPT, acts as a gene-editing "copilot" ...
Good News Network

Scientists Just Made CRISPR 3x More Effective at Treating Genetic Diseases

Scientists developed a new nanostructure that triples CRISPR’s ability to enter cells, unlocking even more power to treat ...